Working… Menu

Dose Escalation Trial of BIBW 2992 Administration in Combination With Docetaxel in Patients With Advanced Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02171741
Recruitment Status : Completed
First Posted : June 24, 2014
Last Update Posted : June 24, 2014
Information provided by (Responsible Party):
Boehringer Ingelheim

Brief Summary:
Study to determine the maximum tolerated dose (MTD) for various treatment durations of BIBW 2992 when administered in combination with docetaxel as determined by drug-related adverse events (AEs) as well as Pharmacokinetics, overall safety and antitumor efficacy.

Condition or disease Intervention/treatment Phase
Neoplasms Drug: BIBW 2992 Drug: Docetaxel Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 31 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Dose Escalation Trial of BIBW 2992 Administration for 20, 13 or 6 Days in Combination With Docetaxel Every 21 Days
Study Start Date : April 2005
Actual Primary Completion Date : December 2007

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Docetaxel + BIBW 2992 Drug: BIBW 2992
continuous daily dosing for 20 or 13 days

Drug: Docetaxel
single infusion on day 1

Primary Outcome Measures :
  1. Incidence and intensity of AdverseEvents according to Common Terminology Criteria (CTCAE version 3) [ Time Frame: up to 32 months ]
  2. Maximum tolerated dose (MTD) of BIBW 2992 [ Time Frame: up to 126 days ]

Secondary Outcome Measures :
  1. Objective tumor response [ Time Frame: up to 32 months ]
  2. Correlation of EGFR (epidermal growth factor receptor), HER2, estrogen receptor (ER) and progesterone receptor (PrR) immunohistochemical status as based on tumor biopsies, or excisions obtained prior to this trial, with objective tumor responses [ Time Frame: up to 32 months ]
  3. Area under the plasma concentration-time curve (AUC) for several time points [ Time Frame: up to 48 hours after administration ]
  4. The percentage of AUC0-∞ that is obtained by extrapolation (%AUCtz-∞) [ Time Frame: up to 48 hours after administration ]
  5. Predose plasma concentration (Cpre) for several time points [ Time Frame: predose on day 10 and 21 ]
  6. Plasma concentration at 24 hours (C24) [ Time Frame: 24 hours after the first and the last adminstration of study drug ]
  7. Maximum measured plasma concentration (Cmax) for several time points [ Time Frame: up to 48 hours after administration ]
  8. Time from dosing to the maximum plasma concentration (tmax) for several time points [ Time Frame: up to 48 hours after administration ]
  9. Terminal half-life (t1/2) for several time points [ Time Frame: up to 48 hours after administration ]
  10. Mean residence time (MRT) for several time points [ Time Frame: up to 48 hours after administration ]
  11. Apparent clearance (CL/F) for several timt points [ Time Frame: up to 48 hours after administration ]
  12. Apparent volume of distribution during the terminal phase (Vz/F) for several time points [ Time Frame: up to 48 hours after administration ]
  13. Terminal rate constant in plasma (λz) [ Time Frame: up to 48 hours after administration ]
  14. Accumulation ratio between day 1 and day 21 with respect to Cmax (Ra1) and AUC (RA2) [ Time Frame: up to day 21 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or female patients with confirmed diagnosis of advanced, non-resectable and / or metastatic solid tumors, of types historically known to express EGFR and/or HER2, who are amenable to docetaxel, preferably patients with breast, prostate, or non-small cell lung cancer. Patients must have failed prior standard therapies associated with clinical benefits, including survival benefits, if such therapies are available. If docetaxel administration is standard therapy associated with clinical benefits, patients are eligible
  • Age 18 years or older
  • Life expectancy of at least three (3) months
  • Written informed consent that is consistent with International Conference on Harmonization - Good Clinical Practice guidelines
  • Eastern Cooperative Oncology Group (ECOG) performance score 0 or 1
  • Patients must have resolution from prior chemo-, hormone-, immuno-, or radiotherapy related toxicities to CTC Grade <= 1or baseline for individual patient
  • Patients must be recovered from previous surgery

Exclusion Criteria:

  • Active infectious disease
  • Gastrointestinal disorders that may interfere with the absorption of the study drug or chronic diarrhea
  • Serious illness or concomitant non-oncological disease considered by the investigator to be incompatible with the protocol
  • Patients with untreated or symptomatic brain metastases. Patients with treated, asymptomatic brain metastases are eligible if there has been no change in brain disease status for at least eight weeks, no history of cerebral edema or bleeding in the past eight weeks and no requirement for steroids or anti-epileptic therapy
  • Cardiac left ventricular function with resting ejection fraction ≥ CTC Grade 1
  • Absolute neutrophil count (ANC) less than 1500 / mm3
  • Platelet count less than 100 000 / mm3
  • Bilirubin > upper limit of normal (ULN)
  • Aspartate amino transferase (AST) and / or alanine amino transferase (ALT) > 1.5 x ULN
  • Alkaline Phosphatase > 2.5 x ULN
  • Serum creatinine > 1.5 mg / dl (> 132 μmol / L, SI (Système Internationale) unit equivalent)
  • Women and men who are sexually active and unwilling to use a medically acceptable method of contraception
  • Pregnancy or breast-feeding
  • Concurrent treatment with other investigational drugs, or chemotherapy, immunotherapy, radiotherapy or hormone therapy (excluding Luteinizing hormone-releasing hormone agonists, or other hormones taken for breast cancer, or bisphosphonates) or participation in another clinical study within the past four weeks before start of therapy or concomitantly with this study
  • Treatment with an EGFR- or HER2 inhibiting drug within the past four weeks before start of therapy or concomitantly with this study (8 weeks for trastuzumab)
  • Patients unable to comply with the protocol
  • Active alcohol or drug abuse
  • Hypersensitivity to docetaxel or any component or other drug formulated with polysorbate 80

The patient may be eligible for re-treatment after the previous course is finished. The patient will not be eligible if any of the following conditions are met:

  • If patients' latest X-ray, CT or MRI reveals progressive disease, or if clinical assessment reveals signs of disease progression
  • Cardiac left ventricular function CTC Grade ≥ 2 at any time during the previous course
  • Patients fulfilling any of the Exclusion Criteria listed before as determined before treatment Day 1 of any new course
  • Patient not recovered from any dose-limiting toxicity (DLT) 14 days after onset. Recovery is defined as a return to baseline level or CTC Grade 1, whichever is higher

Layout table for additonal information
Responsible Party: Boehringer Ingelheim Identifier: NCT02171741     History of Changes
Other Study ID Numbers: 1200.6
First Posted: June 24, 2014    Key Record Dates
Last Update Posted: June 24, 2014
Last Verified: June 2014
Additional relevant MeSH terms:
Layout table for MeSH terms
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Protein Kinase Inhibitors
Enzyme Inhibitors